SAN DIEGO and PENNINGTON, N.J., Nov.
13, 2018 /PRNewswire/ -- OncoSec Medical Inc., (OncoSec)
(NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced that TAVO™ will be
featured in two poster sessions during the 2018 San Antonio Breast
Cancer Symposium (SABCS) taking place December 4-8 in San
Antonio, Texas. Posters include data on
TAVO™ as a monotherapy and an initial project overview
for KEYNOTE-890, a Phase 2 clinical trial in combination with
Merck's KEYTRUDA® (pembrolizumab) for the treatment of late stage
triple negative breast cancer (TNBC).
"We are encouraged with the preliminary clinical observations we
are seeing thus far, both in a monotherapy setting and in
combination with checkpoint inhibitors," said Daniel J. O'Connor, President and Chief
Executive Officer of OncoSec. "Based on this, we are excited to
continue on the path toward developing novel treatment options for
this large unmet medical need,"
Details on the poster presentations are as follows:
Presentation Title: Intratumoral tavokinogene
telseplasmid and electroporation in pre-treated inoperable locally
advanced or recurrent triple-negative breast cancer
Session Date & Time: Thursday,
December 6, 7:00 – 9:00 a.m.
CT (8:00 – 10:00 a.m. ET)
Session Title: Poster Session 2: Treatment:
Immunotherapy (clinical)
Location: Hall 1, Henry B. Gonzalez Convention Center
Presentation Title: A phase 2 study of intratumoral
tavokinogene telseplasmid (tavo) plus electroporation with
pembrolizumab in patients with inoperable locally advanced or
metastatic triple negative breast cancer
Session Date & Time: Thursday,
December 6, 5:00 – 7:00 p.m.
CT (6:00 – 8:00 p.m. ET)
Session Title: Ongoing Clinical Trials: Immunotherapy
Location: Hall 1, Henry B. Gonzalez Convention Center
The abstracts for these presentations are now available online
on the SABCS website at https://www.sabcs.org.
About OncoSec Medical Inc.
OncoSec is a clinical-stage biotechnology company focused on
developing cytokine-based intratumoral immunotherapies to stimulate
the body's immune system to target and attack cancer.
OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline utilizing
TAVO™ as a potential treatment for multiple cancer indications
either as a monotherapy or in combination with leading checkpoint
inhibitors; with the latter potentially enabling OncoSec to address
a great unmet medical need in oncology: anti-PD-1 non-responders.
Results from recently completed clinical studies of TAVO™ have
demonstrated a local immune response, and subsequently, a systemic
effect as either a monotherapy or combination treatment approach.
In addition to TAVO™, OncoSec is identifying and developing new
DNA-encoded therapeutic candidates for use with its ImmunoPulse®
platform. For more information, please visit www.oncosec.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc.
CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-data-in-late-stage-triple-negative-breast-cancer-tnbc-at-the-2018-san-antonio-breast-cancer-symposium-300749119.html
SOURCE OncoSec Medical Incorporated